Clinical Trials Browser

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Biliary Tract Neoplasms

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

Biliary Tract Neoplasms

Biliary Tract Neoplasms

Biliary Tract Neoplasms

Biliary Tract Neoplasms, Colorectal Neoplasms

Biliary Tract Neoplasms

Biliary Tract Neoplasms

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Biliary Tract Neoplasms, Cholangiocarcinoma

Biliary Tract Neoplasms, Carcinoma

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Biliary Tract Neoplasms

Biliary Tract Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Biliary Tract Neoplasms

Biliary Tract Neoplasms, Neoplasm Metastasis

Biliary Tract Neoplasms

Biliary Tract Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Biliary Tract Neoplasms, Liver Neoplasms, Pancreatic Neoplasms, Cholangiocarcinoma

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Biliary Tract Neoplasms

Biliary Tract Neoplasms

Biliary Tract Neoplasms, Gallbladder Neoplasms

Clinical Trials

AB02

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

TOURMALINE

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

DESTINY-BTC01

DVDMS

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

MK-9999-02A

AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer

CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers

Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer

Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

GENTIS

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

The Safety and Efficacy of Benmelstobart Injection in Patients With Advanced Biliary Tract Malignant Tumors

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

TAB-2

Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

SAIB

Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer

SAFIR-ABC10

RUGB